MESIANO, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 610
EU - Europa 202
AS - Asia 160
SA - Sud America 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 976
Nazione #
US - Stati Uniti d'America 604
IT - Italia 71
CN - Cina 62
SG - Singapore 55
IE - Irlanda 35
SE - Svezia 30
VN - Vietnam 18
FI - Finlandia 14
FR - Francia 14
UA - Ucraina 10
DE - Germania 9
ID - Indonesia 8
BE - Belgio 6
KR - Corea 6
CA - Canada 5
HK - Hong Kong 5
GB - Regno Unito 4
NO - Norvegia 4
IN - India 3
JP - Giappone 2
PL - Polonia 2
AR - Argentina 1
BR - Brasile 1
BY - Bielorussia 1
EU - Europa 1
IR - Iran 1
LV - Lettonia 1
MA - Marocco 1
MX - Messico 1
NL - Olanda 1
Totale 976
Città #
Chandler 74
Houston 59
Singapore 45
Fairfield 40
Beijing 37
Dublin 35
Ann Arbor 28
Ashburn 26
Santa Clara 23
Cambridge 22
Nyköping 17
Torino 17
Woodbridge 17
Jacksonville 16
Seattle 16
Turin 12
Columbus 11
Wilmington 11
Princeton 10
Fremont 9
Medford 9
Dearborn 8
Jakarta 8
Villeurbanne 8
Munich 7
Brussels 6
Detroit 6
Dong Ket 6
Shanghai 6
San Diego 5
Helsinki 4
Boardman 3
Boston 3
Cagliari 3
Hanoi 3
Hong Kong 3
Kunming 3
New York 3
Ottawa 3
San Mateo 3
Stavanger 3
Washington 3
Cuneo 2
Fort Worth 2
Guangzhou 2
Hangzhou 2
Nanjing 2
Pisa 2
Toronto 2
Upper Marlboro 2
Warsaw 2
Alessandria 1
Bengaluru 1
Brescia 1
Camporosso 1
Central District 1
Chengdu 1
Council Bluffs 1
Des Moines 1
Düsseldorf 1
Englewood 1
Fuzhou 1
Gorizia 1
Guiyang 1
Hebei 1
Hefei 1
Hermosillo 1
London 1
Los Angeles 1
Mestre 1
Milan 1
Minatomirai 1
Moncalieri 1
Mountain View 1
Mumbai 1
Norwalk 1
Oslo 1
Palermo 1
Pasadena 1
Recife 1
Riverton 1
Rome 1
Rouen 1
Saint-sulpice-et-cameyrac 1
Salé 1
San Nicolas 1
Seoul 1
Settimo Torinese 1
Sìnnai 1
Tamworth 1
Tappahannock 1
Tokyo 1
Wuhan 1
Xian 1
Totale 692
Nome #
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 161
Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity 133
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients 122
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 109
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 96
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 90
Adoptive immunotherapy against sarcomas. 85
Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation 76
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 64
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 41
Targeted lipid-coated ZnO nanoparticles coupled with ultrasound: A sonodynamic approach for the treatment of osteosarcoma as 3D spheroid models 16
Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: Identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity (Journal of Translational Medicine (2018) 16 (237) DOI: 10.1186/s12967-018-1613-5) 12
Totale 1.005
Categoria #
all - tutte 3.654
article - articoli 0
book - libri 0
conference - conferenze 315
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.969


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020116 0 0 0 0 4 52 7 8 6 14 15 10
2020/2021167 10 56 11 7 10 13 4 8 7 8 11 22
2021/2022153 9 2 6 9 9 4 13 11 5 10 51 24
2022/2023224 17 22 2 25 9 58 17 14 38 12 10 0
2023/202499 12 23 7 3 4 15 3 10 0 1 11 10
2024/2025136 8 31 35 23 39 0 0 0 0 0 0 0
Totale 1.005